KRAS and neoplasm: Very recently, the KRASG12C inhibitor sotorasib and the MAP2K4 inhibitor HRX-0233 were shown to synergistically inhibit growth of a number KRAS mutant CRC and lung cancer cell lines and to induce durable tumor shrinkage in mouse xenografts of human lung cancer cells67.